Despite numerous clinical trials, CAR-T therapy remains ineffective against solid tumors due to poor T-cell infiltration, antigen heterogeneity, and an immunosuppressive tumor microenvironment (TME). Traditional in vitro and animal models fail to accurately replicate these key barriers, limiting the ability to select promising CAR-T candidates for clinical translation.
Our vessel-cancer co-culture model provides a physiologically relevant, scalable system for evaluating CAR-T migration, tumor infiltration, and cytotoxicity in a controlled TME-integrated microfluidic platform.
Key Features of the Model:
- Vessel-Tumor Co-Culture – Integrates a perfusable endothelial vessel adjacent to a solid tumor compartment
- T Cell Extravasation & Infiltration – Models CAR-T movement from vasculature to tumor tissue
- Scalable Microfluidic Platform – Supports high-throughput drug and therapy screening
- Live Imaging & Real-Time Tracking – Fluorescently labeled CAR-T cells enable dynamic monitoring
- Customizable Tumor Microenvironment – Supports cancer cell lines, primary tumors, and immune modulators
Download the poster to learn how this model advances solid tumor immunotherapy research
